Log in

Magenta Therapeutics Stock Forecast, Price & News

+0.13 (+1.89 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $7.01
50-Day Range
MA: $6.83
52-Week Range
Now: $7.01
Volume88,675 shs
Average Volume219,168 shs
Market Capitalization$338.62 million
P/E RatioN/A
Dividend YieldN/A
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. Thecompany is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. It has a has a research and clinical collaboration agreement with AVROBIO, Inc.to evaluate targeted antibody-drug conjugate as a conditioning regimen for lentiviral gene therapies. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More
Magenta Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MGTA



Sales & Book Value

Annual SalesN/A
Book Value$3.62 per share


Net Income$-76,770,000.00


Market Cap$338.62 million
Next Earnings Date3/2/2021 (Estimated)
OptionableNot Optionable
+0.13 (+1.89 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions

How has Magenta Therapeutics' stock been impacted by COVID-19?

Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MGTA shares have decreased by 23.5% and is now trading at $7.01.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Magenta Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Magenta Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Magenta Therapeutics?

Wall Street analysts have given Magenta Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Magenta Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Magenta Therapeutics' next earnings date?

Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Magenta Therapeutics

How were Magenta Therapeutics' earnings last quarter?

Magenta Therapeutics, Inc. (NASDAQ:MGTA) issued its earnings results on Thursday, November, 5th. The company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.45) by $0.08.
View Magenta Therapeutics' earnings history

What price target have analysts set for MGTA?

5 Wall Street analysts have issued 1 year price targets for Magenta Therapeutics' shares. Their forecasts range from $15.00 to $22.00. On average, they anticipate Magenta Therapeutics' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 171.0% from the stock's current price.
View analysts' price targets for Magenta Therapeutics

Are investors shorting Magenta Therapeutics?

Magenta Therapeutics saw a increase in short interest in October. As of October 30th, there was short interest totaling 1,870,000 shares, an increase of 16.1% from the October 15th total of 1,610,000 shares. Based on an average daily volume of 216,700 shares, the days-to-cover ratio is presently 8.6 days. Approximately 6.4% of the company's stock are short sold.
View Magenta Therapeutics' Short Interest

Who are some of Magenta Therapeutics' key competitors?

What other stocks do shareholders of Magenta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP).

Who are Magenta Therapeutics' key executives?

Magenta Therapeutics' management team includes the following people:
  • Dr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 49, Pay $747.24k)
  • Dr. John C. Davis Jr., M.D., M.P.H., M.S., Head of R&D and Chief Medical Officer (Age 58, Pay $567.62k)
  • Ms. Cindy Driscoll, Interim Principal Financial & Accounting Officer (Age 55)
  • Dr. Lisa M. Olson Ph.D., Chief Scientific Officer
  • Dr. Zoran Zdraveski J.D., Ph.D., Chief Legal Officer & Corp. Sec. (Age 50)
  • Ms. Kristen Stants, Chief People Officer (Age 47)
  • Dr. Christina K. Isacson, Chief Bus. Officer (Age 41)
  • Ms. Catherine Monaghan, Head of Clinical Devel. Operations
  • Dr. Jan Pinkas Ph.D., Sr. VP & Head of Translational Sciences
  • Dr. Li Malmberg Ph.D., Sr. VP & Head of Manufacturing

When did Magenta Therapeutics IPO?

(MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Magenta Therapeutics' stock symbol?

Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA."

Who are Magenta Therapeutics' major shareholders?

Magenta Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.66%), UBS Asset Management Americas Inc. (1.26%), State Street Corp (0.73%), Morgan Stanley (0.57%), Principal Financial Group Inc. (0.50%) and Truist Financial Corp (0.27%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, Jason Gardner, John C Davis Jr and Michael P Cooke.
View institutional ownership trends for Magenta Therapeutics

Which major investors are selling Magenta Therapeutics stock?

MGTA stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., and State Street Corp. Company insiders that have sold Magenta Therapeutics company stock in the last year include Jason Gardner, John C Davis Jr, and Michael P Cooke.
View insider buying and selling activity for Magenta Therapeutics

Which major investors are buying Magenta Therapeutics stock?

MGTA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Truist Financial Corp, Squarepoint Ops LLC, Cubist Systematic Strategies LLC, Arrowstreet Capital Limited Partnership, ProShare Advisors LLC, and UBS Asset Management Americas Inc..
View insider buying and selling activity for Magenta Therapeutics

How do I buy shares of Magenta Therapeutics?

Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Magenta Therapeutics' stock price today?

One share of MGTA stock can currently be purchased for approximately $7.01.

How big of a company is Magenta Therapeutics?

Magenta Therapeutics has a market capitalization of $338.62 million. The company earns $-76,770,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Magenta Therapeutics employs 72 workers across the globe.

What is Magenta Therapeutics' official website?

The official website for Magenta Therapeutics is www.magentatx.com.

How can I contact Magenta Therapeutics?

Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.